INTRODUCTION AND OBJECTIVES: To-date there are no urine-based tests that provide clinical resolution of the severity or grade of urothelial carcinoma (UC) in patients presenting with primary hematuria. Such information permits timely diagnosis and specific management of hematuria patients identified with high grade and/or advanced UC disease. The objective of this study was, therefore, to develop and investigate the performance of Cxbladder Resolve, a new urine-based test offering identification and accurate segregation of patients with high-grade (HG) and/or late-stage disease at the time of initial urological investigation.
METHODS: Participants in the study (N¼863) were recruited from patients presenting with micro-(n¼66) or macrohematuria (n¼797) across centers in the U.S., New Zealand and Australia. An index incorporating 2 clinical variables and 5 gene expression biomarkers measured in urine was developed to segregate patients into 3 groups: 1. Low risk of UC; 2. Elevated risk of low grade (LG) UC; and 3. High risk of high grade (HG) UC.
RESULTS: Of the 863 recruited patients, 89 (10.3%) primary cases of UC were observed including 40 LG and 49 HG. Cxbladder Resolve segregated the 863 participants into: low risk of UC (n¼479; 55%), elevated risk of LG UC (n¼288; 33%) and high risk of HG UC disease (n¼96; 11%). (Table) Of the 40 patients with LG bladder tumors, 27 were correctly categorized as Elevated risk of low grade UC, with the remainder; 9 as High risk of HG UC, and 4 as Low risk of UC. Of the 49 patients with HG UC, 47 (96%) were correctly identified as having High risk of HG UC and the remaining 2 patients were classified as elevated risk of LG UC. No patients with HG UC were classified as low risk of UC. Overall a negative predictive value [NPV] of ¼99% was observed.
CONCLUSIONS: Cxbladder Resolve accurately identifies over 95% of HG UC patients with a reciprocal high NPV (99%) for low risk patients. The index has a low probability of incorrectly classifying pathologic HG UC patients as low risk. Clinical utility is demonstrated for stratifying hematuria patients into risk groups allowing for prioritization of high risk patients with aggressive disease requiring early investigative procedures. 1998-2001, 2002-2005, 2006-2009 and 2010-2014 and variations in symptom scores and patterns, UPOINT categorization and treatment modalities amongst cohorts were analyzed. Continuous variables were analyzed using ANOVA while categorical variables were analyzed using chi-squared test for trend in proportions.
RESULTS: A total of 1349 patients with CP were evaluated in a single tertiary referral clinic. Bacterial prostatitis patients (n¼39) were excluded. Mean age of the 1310 CP/CPPS patients was 44.7, while mean CPSI pain, urination, quality of life (QOL) and total scores were 10.6, 4.8, 7.9 and 23.3 respectively. Overall, the most prevalent UPOINT domain, urinary (U) (71.8%) predicted for a higher CPSI urination score (6.3), more frequent penile tip pain (37%), dysuria (48%) and more treatment with alpha-blockers (70%). Increase in UPOINT domains predicted higher CPSI pain, QOL and total scores. Pain location did not predict UPOINT domain or treatment modality. Trends over time included increased prevalence of psychosocial (P), organ (O) and tenderness (T) domains as well as increased use of alpha-blockers, neuromodulation and phytotherapy as treatment modalities. There was little variation in age, CPSI scores and pain locations over time.
CONCLUSIONS: The changing clinical face of CP/CPPS reflects the increased recognition of psychosocial and pelvic floor pathology along with the concomitant use of associated therapies. There was little variation of pain/urinary symptom patterns and QOL. The more things 00 appear 00 to change, the more they stay the same. . 197, No. 4S, Supplement, Friday, May 12, 2017 
